Scott Beckstead, DO
Family Medicine · Farmington, UTNPI 1508810854
Payments from drug & device makers
Across 179 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$501
- Abbott$427
- GSK$371
- Boehringer Ingelheim$238
- Astellas Pharma US Inc$228
- Johnson & Johnson$209
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,476100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $501 |
| Abbott | 17 | $427 |
| GSK | 17 | $371 |
| Boehringer Ingelheim | 12 | $238 |
| Astellas Pharma US Inc | 12 | $228 |
| Johnson & Johnson(2 entities) | 12 | $209 |
| Pfizer | 9 | $178 |
| Lilly USA, LLC | 13 | $153 |
| Novo Nordisk | 6 | $104 |
| Exact Sciences | 5 | $83 |
| Regeneron Healthcare Solutions, Inc. | 4 | $77 |
| Dynavax Technologies Corporation | 4 | $72 |
| Shield Therapeutics Inc | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Merck | 3 | $53 |
| Redhill Biopharma Inc. | 3 | $52 |
| Bayer | 3 | $48 |
| Impel Pharmaceuticals Inc. | 3 | $45 |
| Nestle Healthcare Nutrition Inc. | 3 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Organon | 3 | $38 |
| QOL Medical, LLC | 2 | $36 |
| AstraZeneca | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Edwards Lifesciences | 1 | $23 |
| Tris Pharma Inc | 1 | $22 |
| Seqirus USA Inc | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Lucid Diagnostics Inc. | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $18 |
| BD | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Biogen | 1 | $16 |
| Amgen | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$125
- VRAYLAR$125
- AREXVY$122
How this compares
$3,476 in reported general payments places this provider in the 75th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 23 | $28,237 |
| XareltoRivaroxaban | 20 | $26,489 |
| FarxigaDapagliflozin Propanediol | 15 | $25,495 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $22,334 |
| TrulicityDulaglutide | 21 | $21,778 |
| MyrbetriqMirabegron | 22 | $17,420 |
| EliquisApixaban | 19 | $16,960 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $16,702 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $6,003 |
| Rosuvastatin Calcium | 186 | $3,001 |
| Levothyroxine Sodium | 219 | $2,589 |
| Omeprazole | 123 | $2,273 |
| Potassium Chloride | 100 | $1,976 |
| Esomeprazole Magnesium | 28 | $1,736 |
| Gabapentin | 81 | $1,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $104 | $28,23723 claims |
| Johnson & JohnsonXarelto | $209 | $26,48920 claims |
| AstraZenecaFarxiga | $35 | $25,49515 claims |
| Lilly USA, LLCTrulicity | $153 | $21,77821 claims |
| Astellas Pharma US IncMyrbetriq | $228 | $17,42022 claims |
| PfizerEliquis | $178 | $16,96019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 928 family medicine providers in Utah.
Other family medicine in Farmington
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
- Sarang YoonSalt Lake City$9.4M
- Michael AdamsSandy$8.1M
- Katie JulienSouth Jordan$7.1M
- Scott EricksonBountiful$3.7M
- John RichardsSouth Jordan$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.